Wes Burk, cofounder and vice president of Emerald Scientific, discusses this year's Emerald Conference, some of Emerald’s other initiatives in cannabis science, and their plans going into 2020
The Emerald Conference will be taking place in a few short weeks (February 26–29) in beautiful San Diego, California. We recently spoke with Wes Burk, cofounder and vice president of Emerald Scientific, about the conference, some of Emerald’s other initiatives in cannabis science, and their plans going into 2020.
What’s new at this year’s Emerald Conference? What do you look forward to the most?
Wes Burk: The most exciting thing about this year’s Emerald Conference is the content. We have a 31-member scientific committee that has helped curate the content and quality of presentations, so this year promises to be even more cutting edge than previous years. Additionally, we have added a “Quality Summit” on Saturday which will focus on current good manufacturing practices (cGMP), standardization, and features a special Nomenclature Workshop. These are pressing topics that this industry is currently feverishly addressing.
It was recently announced that The Emerald Conference was purchased by Marijuana Business Daily (MJBiz). How will that acquisition change future editions of The Emerald Conference? Do you hope to expand your reach of bringing cannabis science to a broader audience?
Burk: This acquisition represents an evolution in a long standing relationship between MJBiz Daily and Emerald Scientific. The partnership will continue and allows each organization to leverage its strengths. MJBiz will bring logistics, support, and exposure for the conference to an unprecedented level allowing Emerald Scientific to continue to collaborate on the curation of scientific content. We will certainly reach a broader audience such as bio tech and life sciences while continuing to set the standard for content. This is a very positive partnership for all of cannabis science!
What prompted you to create your webinar series Extraction Efficiency? What feedback or engagement have you received?
Burk: The Emerald Extraction Efficiency series was created to introduce newer extraction professionals to the complexities of supercritical extraction and help inspire a more sophisticated approach to running extraction labs. There are so many variables that need to be understood and managed to tune extractions and thereby maximize return on investment (ROI) for those operations. The Emerald Extraction Efficiency series does a great job of discussing best practices around which to build processes.
Can you talk about your work with the development of the Emerald Test? What have you learned through executing this test?
Burk: The Emerald Test was created to help quality assurance labs meet oversight and accreditation requirements. It has evolved into an industry benchmark, showing trends and areas of challenge for analysis of what is a very complex plant with ever evolving matrixes that must be dealt with.
What advice would you give to labs that have not yet enrolled in the Emerald Test?
Burk: Not only does the Emerald Test satisfy regulatory requirements and accreditation requirements in most cases, it also gives a lab the ability to see how they perform compared to other labs around the world due to the Inter-Laboratory Comparison component of the test. If a lab performs well, they also receive the Emerald Badge which can be used to show the public they are proficient in these disciplines and many labs are using their badges aggressively in their marketing.
What other standards or accreditations do you want to see established in the cannabis industry?
Burk: When it comes to standards, what we would most like to see is the creation and validation of standard methods for across the major testing categories: potency, residual solvents, microbial, heavy metals, and pesticide analysis. This would be a tremendous step towards ensuring consumers can better trust the labels and make sound purchasing decisions normalizing outcomes to expectations.
Through your company Emerald Scientific, the Emerald Conference, your webinar series on extractions, your help developing the Emerald Test, and your advocacy, what do you most want to accomplish for the cannabis industry?
Burk: One of the core values that Emerald Scientific is proud to promote is quality science. Only through rigorous science can we build an industry on predictable, reliable outcomes for patients and consumers and only then can we expect our industry to continue to thrive.
You have developed so many tools and resources for the industry, what’s next for you?
Burk: 2020 promises to be a very exciting year for Emerald Scientific! We have just launched our Canadian subsidiary and we look forward to the new opportunities and relationships we are forging there. We are also proud of our newly announced partnership with PerkinElmer and now, with capital instrumentation, are thrilled to bring a full suite of solutions to the cannabis industry.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Empowering Women in Cannabis: Susan Audino, PhD, on Inclusivity, Integrity, and Industry Challenges
December 11th 2024Founder of S. A. Audino & Associates, LLC, Susan Audino, PhD, recently co-founded Saturn Scientific, LLC, a collaboration of five experienced individuals providing unbiased evaluations on the data and science for stakeholders in the cannabis industry. In this interview with Cannabis Science and Technology, Dr. Audino shares her unexpected path into analytical science and the cannabis industry as well as the obstacles she’s faced throughout her career. She highlights the gender bias she’s observed, such as unequal recognition of credentials and workplace challenges, while advocating for inclusivity and mentorship to empower women in science. Additionally, Dr. Audino recounts her experiences of navigating the male-dominated cannabis space, pushing for transparency, collaboration, and integrity in laboratory practices. Ultimately, Audino believes fostering mutual respect and knowledge-sharing is vital for the industry’s growth and resilience.
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Inside the University of Maryland School of Pharmacy’s Graduate Program in Medical Cannabis
September 16th 2024Leah Sera, PharmD, MA, the co-program director for the University of Maryland School of Pharmacy’s Graduate Studies in Medical Cannabis program sat down with Cannabis Science and Technology to discuss higher education in medical cannabis.